Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

810.01 +10.21 (+1.28%)
Streaming Delayed Price Updated: 11:42 AM EST, Dec 3, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,003,915
Open 802.93
Bid (Size) 810.01 (7)
Ask (Size) 810.80 (7)
Prev. Close 799.80
Today's Range 801.61 - 816.20
52wk Range 561.65 - 972.53
Shares Outstanding N/A
Dividend Yield 0.64%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Weight Loss Drug Wars Heat Up: Amgen Challenges Eli Lilly, Novo's Dominance
Amgen's new obesity drug, MariTide, shows promise against giants Eli Lilly and Novo Nordisk, but faces tough competition in a $100B market. 
Via Benzinga
Want To Bet On Ozempic, Wegovy Success? Defiance Introduces Leveraged ETF To Capture Novo Nordisk Momentum
Defiance ETFs introduces NVOX, a leveraged ETF offering 2X exposure to Novo Nordisk's stock price movements, targeting the booming weight loss market with tactical trading opportunities. 
Via Benzinga
Topics ETFs

Performance

YTD
+36.78%
+36.78%
1 Month
+0.48%
+0.48%
3 Month
-15.32%
-15.32%
6 Month
-2.56%
-2.56%
1 Year
+38.30%
+38.30%

More News

Read More
Eli Lilly Gap
Via Talk Markets
Topics Stocks / Equities
It’s Been A Tough Month For Healthcare Stocks
Via Talk Markets
Topics ETFs Stocks / Equities
Macy's Multimillion-Dollar Error
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
Behind the Scenes of Eli Lilly's Latest Options Trends
Via Benzinga
Why Amgen's Weight Loss Result Is a Win for Eli Lilly
Via The Motley Fool
Big Pharma Pushes To Revise Biden-era Medicare Drug Price Negotiation Law Under Trump
Via Benzinga
Weight Loss Drugs Like Wegovy, Zepbound Linked To Reduced Alcohol Use: Study
Via Benzinga
Prediction: This Unstoppable Vanguard ETF Will Beat the S&P 500 Again in 2025
Via The Motley Fool
Topics ETFs Stocks
Exposures US Equities
Down 12.3% at One Point in a Single Trading Session, Is Amgen Stock Still a Buy?
Via The Motley Fool
Bristol-Myers Squibb Files Lawsuit Against US Agency For Overreach In 340B Drug Pricing Program
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Viking Therapeutics Stock On Brink Of Death Cross As Weight Loss Hype Loses Momentum
Via Benzinga
Does Billionaire Israel Englander Know Something Wall Street Doesn't? The Billionaire Investor Just Sold 8.1 Million Shares of Walmart Stock.
Via The Motley Fool
Stock Market Hits Highs Despite Trump Tariff Threats, Nvidia, Tech Turkeys: Weekly Review
Via Investor's Business Daily
Topics Government
Exposures Political
Eli Lilly, Pfizer, and AstraZeneca: 2025 Vaccine Makers to Watch
Via MarketBeat
Topics Government
Exposures COVID-19 Political Product Safety
Down More Than 20% From Its High, Is Now the Time to Buy Eli Lilly Stock?
Via The Motley Fool
LeapFrog Investments raises more than $1 billion for impact health investing
Via Equities.com
The Ultimate Pharmaceutical Stock to Buy With $1,000 Right Now
Via The Motley Fool
Tradepulse Power Inflow Alert: Eli Lilly & Company Climbs Over 22 Points After Alert
Via Benzinga
Stocks Mixed Ahead Of Fed Minutes, Mexican Peso Tumbles To Over 2-Year Lows On Tariffs Fears: What's Driving Markets Tuesday?
Via Benzinga
Topics Economy
Exposures Interest Rates
Biden Proposes Medicare, Medicaid Access For Popular Weight-Loss Drugs
Via Benzinga
Eli Lilly Stock Is Rising Tuesday: What's Going On?
Via Benzinga
Amgen Crashes 12% After Weight-Loss Drug Meets Eli Lilly's In A Key Test
Via Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.